Study of utidelone and toripalimab for advanced cervical cancer
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial tests a combination of two drugs, utidelone and toripalimab, for people with advanced cervical cancer that has come back or spread. The goal is to see if this treatment can shrink tumors or slow the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 to 75 years old.
- You must have advanced cervical cancer that has come back or spread and has been confirmed by a biopsy.
- You must have had at least one round of standard chemotherapy for your advanced cancer, or your cancer got worse within 6 months after previous treatment with radiation and chemotherapy together.
- Any side effects from past treatments should have mostly gone away (except for hair loss).
- You must have good enough blood counts, liver function, and kidney function based on blood tests.
- You must agree to use effective birth control during the study and for at least 90 days after the last dose.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of the immunotherapy drug toripalimab with chemotherapy for women with locally advanced cervical cancer that has not been treated yet. The goal is to see if this approach can shrink tumors before standard radiation therapy.
This trial combines the immunotherapy drug toripalimab with standard chemoradiation to treat newly diagnosed advanced cervical cancer. It aims to see if adding toripalimab improves outcomes for patients whose cancer has not spread to distant organs.
This trial tests whether adding two immunotherapy drugs (iparomlimab and tuvonralimab) to standard chemoradiation can help people with cervical cancer that has returned or spread to a few new places. The goal is to see if this combination improves outcomes for those whose cancer is no longer responding to initial treatment.
This study tests whether combining immunotherapy with chemotherapy, followed by radiation plus immunotherapy, can work better than standard treatment for cervical cancer. It aims to help patients whose cancer has not spread yet.
This Phase 1/2 study tests a combination medicine (ILB-2109) plus an immune therapy (toripalimab) in people with advanced solid tumors when standard treatments haven’t worked or aren’t available. It aims to find out if the treatment can shrink tumors and is safe enough to keep studying.
This trial tests a combination of two drugs, WX390 and Toripalimab, against standard treatments for recurrent or metastatic cervical cancer that has worsened after platinum-based chemotherapy. It aims to find a more effective treatment option.
Hear when a new Cervical Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.